Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) just unveiled an announcement.
On January 31, 2025, OKYO Pharma Limited announced that its CEO, Gary S. Jacob, and Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, have purchased a total of 30,000 ordinary shares on NASDAQ, each at a price of US$1.04 per share. This acquisition increases Mr. Cerrone’s holdings to nearly 29% of the company’s issued share capital, signaling confidence in the company’s strategic positioning in the biopharmaceutical industry focused on eye disease therapies.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED). The company is engaged in the discovery and development of novel molecules to address these conditions, with its shares traded on the NASDAQ Capital Market. OKYO is currently conducting Phase 2 trials for its OK-101 treatment targeting both DED and NCP.
YTD Price Performance: -2.65%
Average Trading Volume: 126,866
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $37.27M
See more data about OKYO stock on TipRanks’ Stock Analysis page.
